UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 13, 2020
SELECTA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-37798 | 26-1622110 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
480 Arsenal Way
Watertown, MA 02472
(Address of principal executive offices) (Zip Code)
(617) 923-1400
Registrant’s telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: | ||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, | SELB | Nasdaq Global Market |
$0.0001 par value per share | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ý
Item 7.01. Regulation FD Disclosure.
Selecta Biosciences, Inc. (the “Company”) from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.
The information in Item 7.01 of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed.
Exhibit No. | Description | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SELECTA BIOSCIENCES, INC. | ||
Date: January 13, 2020 | By: | /s/ Carsten Brunn, Ph.D. |
Carsten Brunn, Ph.D. | ||
President and Chief Executive Officer | ||
Corporate Presentation January 2020 SELB
Safe harbor/disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the progress of the clinical development of SEL-212, the anticipated timing of the head-to-head trial comparing SEL-212 and Krystexxa® and related data readouts, whether the head-to-head trial with Krystexxa will demonstrate superiority, provide rapid results or de-risk the Phase 3 trials for SEL-212, the company’s ability to enroll patients in its clinical trials, the potential of ImmTOR™ to reduce AAV vector immunogenicity and enable re-dosing of AAV gene therapy without neutralizing antibody formation or loss of therapy expression, the anticipated timing of preclinical toxicology studies in AAV gene therapy and initiation of a clinical trial related thereto, the potential of SEL-212 to serve unmet needs in chronic refractory gout patients including sustained sUA reduction, reduced flares, and once monthly dosing, the anticipated timing for advancing into Phase 3 if at all, the anticipated timing of the company’s plans to meet with the U.S. Food and Drug Administration, the ability of the company’s ImmTOR technology to induce immune tolerance and mitigate antigen-specific neutralizing antibody formation, the scalability of the company’s manufacturing processes, the potential of ImmTOR to enable sustained therapeutic activity of biologic therapies, whether current evaluable SEL-212 patients will be predictive of future evaluable SEL-212 patients, whether maintained SUA level reduction correlates with low and/or negative drug-specific antibody titers, the potential of SEL-212 to significantly reduce tophi/heavy urate burden and/or rapidly eliminate tissue urate burden, whether SEL-212 has the ability to reduce gout flares frequency initially and over time during SEL-212 therapy, anticipated achievement of key milestones for the company’s chronic refractory gout and gene therapy programs, the company’s ability to execute on its strategic priorities, advance its ImmTOR platform, and grow its strategic partnerships, the potential of the company’s partnership with Asklepios BioPharmaceutical, Inc. to address unmet medical need in patients with rare diseases, the amount of upfront and milestone payments that Selecta is eligible to receive pursuant to its license agreement with Asklepios BioPharmaceutical, Inc., the company’s expected cash position and runway, the billion dollar market potential of the chronic refractory gout market, the ability of the company’s ImmTOR platform to unlock the full potential of biologic therapies, the potential of SEL-212 to enable sustained efficacy in chronic refractory gout patients and resolve their symptoms, the potential treatment applications for products utilizing the ImmTOR platform in areas such as enzyme therapy and gene therapy, the potential of AAV gene therapy to transform the future in a variety of inherited and acquired diseases, the potential of the ImmTOR platform generally, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hypothesize,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, the following: the uncertainties inherent in the initiation, completion and cost of clinical trials including their uncertain outcomes, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a particular clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, the unproven approach of the company’s ImmTOR technology, potential delays in enrollment of patients, undesirable side effects of the company’s product candidates, its reliance on third parties to manufacture its product candidates and to conduct its clinical trials, the company’s inability to maintain its existing or future collaborations, proprietary programs, licenses or contractual relationships, the ability of Asklepios BioPharmaceutical, Inc. to develop products under the license agreement to treat pompe disease, the company’s inability to protect its proprietary technology and intellectual property, potential delays in regulatory approvals, the availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements, the possibility that the company’s recurring losses from operations and negative cash flows from operations could raise substantial doubt regarding its ability to continue as a going concern, substantial fluctuation in the price of its common stock, the company’s strategy may change, and the company may not be able to effectively implement its current strategic plan, the size of the company’s workforce following the restructuring may not be sufficient, and the company may not be able to effectively attract or retain new employees, risks associated with the restructuring, such as employee claims and the risk that the actual financial and other impacts of the reduction could vary materially from the outcomes anticipated, and other important factors discussed in the “Risk Factors” section of the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 8, 2019, and in other filings that the company makes with the Securities and Exchange Commission. In addition, any forward-looking statements included in this presentation represent the company’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. The company specifically disclaims any obligation to update any forward-looking statements included in this presentation. 2
Selecta well-positioned for success Tolerogenic platform – Selecta’s immune tolerance platform, ImmTOR, could unlock the full potential of biologic therapies by mitigating Neutralizing Antibody (Nab) formation — Pipeline focused on therapeutic biologics/enzymes and AAV gene therapies Lead program – SEL-212, addressing a $1B+ chronic refractory gout market with high unmet need — COMPARE trial ongoing to evaluate efficacy and safety of SEL-212 vs. KRYSTEXXA ® o Announced completion of enrollment in December 2019, with 150 patients enrolled (75 patients per arm) o Top-line data, including statistical superiority, planned for mid 2020 — FDA meeting in January 2020 regarding Phase 3 clinical development plan Pipeline – gene therapy program to enter the clinic in 2020 — Preclinical results suggest high relevance to diseases which may require re-dosing gene therapies to maintain efficacy — Several collaborations & licensing agreements with leading gene therapy players o 50/50 collaboration agreement with AskBio o License agreement with AskBio for Pompe disease o License agreement with Spark for Hemophilia A Appointed Carrie S. Cox as Chairman of the Company’s Board of Directors in November 2019 Completed $70 million private placement in December 2019 3
ImmTOR Immune Tolerance Platform 4
Biologic therapies may trigger NAbs that negate their therapeutic benefit There is a significant unmet Dendritic cells play a key need for a technology that role in immune tolerance, selectively induces immune providing a promising target tolerance to mitigate unwanted antigen-specific immune responses Inducing selective immune tolerance for biologic therapies considered the “Holy Grail” 5
ImmTOR has the potential ability to enable sustained therapeutic activity of biologic therapies and unlock their potential Co-administer with biologic therapies to mitigate antigen- specific NAb formation Induce a tolerogenic message from the dendritic cell to naïve T cells to develop into T regulatory cells Promote selective immune tolerance of the biologic therapy 6
SEL-212 (ImmTOR+pegadricase) for Chronic Refractory Gout 7
Chronic refractory gout is a severe form of inflammatory arthritis with a significant impact on patients Chronic disease can lead How chronic 34% 28% 23% refractory gout to sequelae including: patients describe Severe Breaking Glass Bone erosions their flare pain burn a bone piercing skin Tophi Chronic pain How long chronic Joint deformities Loss of function refractory gout flares 7 to 14 can last days Disability Annual lost productivity (pts<65) ~25 days Estimated # of patients diagnosed in US with chronic ~160,000 refractory gout 8
Significant need for effective new therapies in chronic refractory gout Improved efficacy, allowing patients to complete full 6-month therapy cycle — Persistent reduction in Serum Uric Acid (SUA) levels — Elimination of tophi Monthly dosing Gout flare reduction Avoidance of “off-label” and global immunosuppressive therapies SEL-212 has the potential to address these unmet needs and holds $1B+ market potential 9
Sustained reduction of SUA with monthly dosing of SEL-212 was observed in Phase 2 dose ranging study Phase 2 results after 20 weeks of once-monthly SEL-212 treatment: SEL-212 SEL-212 SEL-212 SEL-212 SEL-212 100 66% (21/32)* 50 0 % Pts. SUA <6 mg/dL % Pts. SUA 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Weeks after initiation 66% of evaluable patients completed the 20-week period with an SUA level <6 mg/dL *Week 20 Evaluable patients = patients who received a full first dose and did not discontinue due to any measure other than drug effectiveness or drug related safety 10
Dual energy computed tomography (DECT) scan images show reduction of tissue urate burden Baseline Week 11 Week 20 https://selectabio.com/wp-content/uploads/2018/10/ACR-poster-DECT-2018-FINAL-.pdf 11
Phase 2 data showed reduced frequency and severity of flares during SEL-212 therapy Percent of SEL-212 patients who had flares Severity of flares % of patients % of patients 64% 29% 24% 32% 12% 9% 3% 4% 1 2 3 4 5 Mild Medium Severe Months after initiation of treatment • Majority of flares occurred in months 1 & 2, with no new patients who flared after month 2 • 96% of flares were mild or moderate in severity • No gout flares were classified as SAEs nor resulted in study drug discontinuations Unaudited data reported as of October 09, 2018 | Clinicaltrials.gov NCT02959918 12
SEL-212 has been generally well tolerated SEL-212 was generally well tolerated at clinically Serious infusion reactions (%) active doses following >470 administrations during the Phase 2 trial 4 0 ) 3 3 .3 % ( n 3 0 23 SAEs reported in the Phase 2 trial o i t c 14 were reported not to be or unlikely to be related to study drug a 2 0 e r 9 were infusion reactions which decreased in incidence with n o i 1 0 8 .3 increasing doses of ImmTOR s 6 .1 u f n 1 .6 I 0 All SAEs were successfully treated without N = 2 /6 N = 3 /3 6 N = 3 /4 9 N = 1 /6 1 further issues P e g a d ric a s e + + + + Im m T O R 0 .0 5 - 0 .1 0 - 0 .1 5 (m g /k g ) 0 .0 8 0 .1 2 5 Unaudited data reported as of February 25, 2019 | Clinicaltrials.gov NCT02959918 13
Comparing the efficacy of SEL-212 to KRYSTEXXA® in gout patients refractory to conventional therapy SEL-212 (N=~75) 6 Infusions Once Monthly 0.15 mg/kg ImmTOR + 0.2 mg/kg of pegadricase Primary Endpoint: Statistical superiority for SUA level < 6mg/dL at 6 months ~150 Refractory Randomized Multiple Secondary Endpoints: Flares, QoL, Chronic Gout Patients HAQ, tophi resolution Safety Assessment KRYSTEXXA® (N=~75) 12 Infusions Every 2 weeks 8mg Head-to-head trial is designed to provide objective, comparative results SUA level reduction, a robust primary endpoint Adult patient population with for approval, can be seen soon after dosing two active arms ‒ Easy to measure Opportunity to test revised ‒ Maintenance strongly correlated with stopping rules and de-risk low/negative drug-specific antibody titers Phase 3 program 14
ImmTOR in Gene Therapy 15
The ability to re-dose AAV gene therapy is a key goal to unlocking the full therapeutic potential Dose titration Dose titration Potential to increase proportion of patients who achieve Therapeutic target zone therapeutic benefit without risk of overdosing Goal of improving enrollment in clinical trials Activity Multiple vector administrations Time (months) Provide potential to target systemic diseases in which multiple vector administrations are likely needed to Rescue of expression achieve full therapeutic efficacy Rescue of expression Allows for potential rescue in patients with organ damage Potential to restore therapeutic expression in pediatric patients as they grow 16
In preclinical studies, ImmTOR induced antigen-specific immune tolerance Treatment Challenge ImmTOR provided AAV-specific AAV8 + ImmTOR AAV8 or AAV5 immune tolerance AAV8 + Empty NP NAbs did not develop in mice treated with ImmTOR+AAV vector Day 0 Day 21 Mice treated with empty nanoparticle (NP) + AAV vector developed significant IgG response AAV8 Challenge AAV5 Challenge When challenged with a different AAV vector, both arms mounted an immune response, suggesting antigen-specific immune tolerance rather than broad immunosuppression was achieved Empty NP ImmTOR Meliani et al., Nature Communications, In Oct. 2018 17
Preclinical data indicates potential of ImmTOR-powered re-dosing in gene therapy ImmTOR-powered AAV8 gene therapy has potential to be re-dosed without NAb formation or loss of therapy expression ImmTOR or Empty NP ImmTOR or Empty NP + AAV8-Luc AAV8-Factor IX Day 0 21 54 Anti-AAV8 Antibody Titer Serum Factor IX Expression 200,000 25,000 r 2 5 0 0 0 160,000 e t i 2 020,0000 0 0 T 120,000 8 1 515,0000 0 0 V 80,000 A AAV8 Titer AAV8 - 1 010,0000 0 0 A - i t 40,000 Anti 5,000 5 0 0 0 Human FIX (ng/mL) n A 00 0 00 2200 4400 6600 34 41 54 D Daysa y s Days Meliani et al., Nature Communications, In Oct. 2018 18
First dose benefit of ImmTOR on liver-directed transgene expression Day 0 Day 56 AAV8-SEAP AAV8-SEAP AAV8-SEAP + ImmTOR AAV8-SEAP + ImmTOR ) U 15000 L R ( P 10000 A E S 5000 m u r e S 0 11 46 63 77 Days First dose benefit is immediate and independent of effect on adaptive immune response Cumulative benefit of first dose and repeat dose provides up to 4-fold increase in transgene expression Ilyinskii et al., Tolerogenic ImmTOR™ nanoparticles enhance vector transduction, mRNA 19 synthesis and transgene expression after initial and repeated administrations of AAV-based gene therapy vectors, Nov. 2019
Opportunities for clinical POC in gene therapy Collaboration Proprietary Program License Agreements AskBio OTC (Ornithine Transcarbamylase AskBio – Development pipeline and deficiency) – Licensed ImmTOR for pompe human trials planned for disease in December 2019; repeat dosing of AAV-based Selecta eligible to receive upfront gene therapies to address and milestone payments of over the unmet medical need for $240 million patients with rare and orphan genetic diseases Spark Therapeutics – Lead indication is MMA – Licensed ImmTOR for hemophilia A (Methylmalonic Acidemia) – Expect to enter the clinic under this collaboration in 2020 20
Financial Overview and Projected Milestones 21
Financial snapshot State For the Quarter Ended September 30, 2019 (In thousands) Research & Development Expenses $8,104 General & Administrative Expenses $3,690 Total Operating Expenses $11,794 Net Loss $(11,994) As of September 30, 2019 (In thousands, except shares outstanding) Cash, Cash Equivalents, Marketable Securities, Restricted Cash $35,892 Shares Outstanding 48,196,387 Completed $70 million private placement in December 2019 22
Projected upcoming milestones Guidance from FDA meeting regarding Phase 3 clinical development plan (Q1 2020) Report top-line data from SEL-212 vs. KRYSTEXXA® COMPARE trial in chronic refractory gout (mid 2020) Planning to commence clinical trial of ImmTOR in gene therapy (2020) 23
Relentlessly committed to overcoming OUR PURPOSE IMMUNOGENICITY with our pioneering ImmTOR immune tolerance platform to transform the lives of patients and their families 24